News | December 26, 2025
Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
mRNA-1010 demonstrated superior relative vaccine efficacy
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Subscribe To Our Newsletter & Stay Updated
